KR20220044534A - 조작된 인터류킨-2 수용체 베타 효능제 - Google Patents
조작된 인터류킨-2 수용체 베타 효능제 Download PDFInfo
- Publication number
- KR20220044534A KR20220044534A KR1020227007082A KR20227007082A KR20220044534A KR 20220044534 A KR20220044534 A KR 20220044534A KR 1020227007082 A KR1020227007082 A KR 1020227007082A KR 20227007082 A KR20227007082 A KR 20227007082A KR 20220044534 A KR20220044534 A KR 20220044534A
- Authority
- KR
- South Korea
- Prior art keywords
- leu
- thr
- lys
- engineered
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886148P | 2019-08-13 | 2019-08-13 | |
| US62/886,148 | 2019-08-13 | ||
| PCT/US2020/046244 WO2021030633A1 (en) | 2019-08-13 | 2020-08-13 | Engineered interleukin-2 receptor beta agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220044534A true KR20220044534A (ko) | 2022-04-08 |
Family
ID=72243240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227007082A Pending KR20220044534A (ko) | 2019-08-13 | 2020-08-13 | 조작된 인터류킨-2 수용체 베타 효능제 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230002466A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4013774A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7783164B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220044534A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114787182A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020329290A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147677A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021030633A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| BR112022017656A2 (pt) * | 2020-03-05 | 2022-10-18 | Univ Leland Stanford Junior | Variantes de il-2 concebidas |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| IL304365B2 (en) | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| EP4373848A2 (en) * | 2021-07-22 | 2024-05-29 | University of Dundee | Therapeutic muteins |
| CN113603791A (zh) * | 2021-08-11 | 2021-11-05 | 厦门目青股权投资合伙企业(有限合伙) | 一种融合蛋白及其应用 |
| WO2023220597A1 (en) * | 2022-05-10 | 2023-11-16 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta reduced-binding agonist |
| WO2025010341A2 (en) * | 2023-07-05 | 2025-01-09 | The Trustees Of Dartmouth College | Cytokine hybrid proteins and methods related thereto |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| IL131016A (en) | 1997-01-21 | 2004-12-15 | Gen Hospital Corp | Selection of proteins using RNA-protein blends |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| CN102816241B (zh) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | 清蛋白融合蛋白 |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP2009542592A (ja) * | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2媒介性免疫応答の有効性を高める組成物および方法 |
| WO2012088446A1 (en) * | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN105440123B (zh) * | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
| WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN109608550B (zh) * | 2012-12-05 | 2020-09-11 | 生控基因疫苗股份有限公司 | 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白 |
| JP6592505B2 (ja) * | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| WO2016126719A1 (en) * | 2015-02-03 | 2016-08-11 | Jyant Technologies, Inc. | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| TWI833684B (zh) * | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| US12522640B2 (en) * | 2018-07-24 | 2026-01-13 | BioNTech SE | IL2 agonists |
-
2020
- 2020-08-13 CN CN202080066791.1A patent/CN114787182A/zh active Pending
- 2020-08-13 KR KR1020227007082A patent/KR20220044534A/ko active Pending
- 2020-08-13 EP EP20761980.0A patent/EP4013774A1/en active Pending
- 2020-08-13 CA CA3147677A patent/CA3147677A1/en active Pending
- 2020-08-13 JP JP2022509060A patent/JP7783164B2/ja active Active
- 2020-08-13 WO PCT/US2020/046244 patent/WO2021030633A1/en not_active Ceased
- 2020-08-13 US US17/634,688 patent/US20230002466A1/en active Pending
- 2020-08-13 AU AU2020329290A patent/AU2020329290A1/en not_active Abandoned
-
2025
- 2025-11-26 JP JP2025203501A patent/JP2026032136A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022544785A (ja) | 2022-10-21 |
| WO2021030633A1 (en) | 2021-02-18 |
| CN114787182A (zh) | 2022-07-22 |
| JP7783164B2 (ja) | 2025-12-09 |
| CA3147677A1 (en) | 2021-02-18 |
| US20230002466A1 (en) | 2023-01-05 |
| AU2020329290A1 (en) | 2022-03-24 |
| JP2026032136A (ja) | 2026-02-25 |
| EP4013774A1 (en) | 2022-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7783164B2 (ja) | 改変インターロイキン2受容体ベータアゴニスト | |
| JP7459186B2 (ja) | 標的化4-1bb(cd137)アゴニストとの併用療法 | |
| US20230227584A1 (en) | Bispecific antibodies comprising a modified c-terminal crossfab fragment | |
| JP7098725B2 (ja) | 二重特異性2+1コントースボディ | |
| JP7148539B2 (ja) | 免疫抱合体 | |
| JP7857236B2 (ja) | 免疫活性化Fcドメイン結合分子 | |
| JP2022062001A (ja) | 抗pd-1抗体と突然変異il-2とまたはil-15とのイムノコンジュゲート | |
| JP2024138240A (ja) | 新規の二重特異性アゴニスト4-1bb抗原結合分子 | |
| US20190352362A1 (en) | LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS | |
| KR20180012260A (ko) | 조율가능한 친화성을 갖는 면역조절 단백질 | |
| US20240376171A1 (en) | Protease-activated polypeptides | |
| JP2023509952A (ja) | 新規4-1bbl三量体含有抗原結合分子 | |
| JP2018153188A (ja) | 二重特異性t細胞活性化抗原結合分子 | |
| KR20230020022A (ko) | Ctla-4 변이체 면역조절 단백질 및 이의 용도 | |
| JP2024522340A (ja) | EpCAMを標的とするアゴニストCD28抗原結合分子 | |
| KR20240024241A (ko) | 인터루킨 15 변이체 | |
| US20250326813A1 (en) | Engineered interleukin-2 receptor beta reduced-binding agonist | |
| HK40076453A (en) | Engineered interleukin-2 receptor beta agonists | |
| HK40103919A (en) | Protease-activated polypeptides | |
| KR20220033140A (ko) | Pd-1-표적화된 il-2 변이체 면역사이토카인 및 인간 pd-l1에 대한 항체의 병용 요법 | |
| HK40091599A (en) | Immune activating fc domain binding molecules | |
| JP2022045530A (ja) | Pd-1標的化il-2変異体免疫サイトカインとヒトpd-l1に対する抗体との併用療法 | |
| HK40078517A (en) | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 | |
| HK1236976B (en) | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |